- AbbVie has completed its acquisition of ImmunoGen.
- The acquisition includes ImmunoGen’s flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC).
- The acquisition is expected to expand AbbVie’s oncology pipeline and drive long-term revenue growth.
AbbVie, a global biopharmaceutical company, announced on February 12, 2024, that it has completed its acquisition of ImmunoGen. This acquisition includes ImmunoGen’s flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx), a treatment for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC).
The acquisition took place in North Chicago, Illinois. The deal is expected to bolster AbbVie’s existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies. ImmunoGen’s late-stage development programs for ELAHERE provide an opportunity to expand into earlier lines of therapy and additional patient populations.
Robert A. Michael, president and chief operating officer, AbbVie, said, “Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with cancer.” He added that the addition of ImmunoGen’s treatment for ovarian cancer will accelerate their ability to help patients today, expand their oncology pipeline, and drive long-term revenue growth well into the next decade.
The FDA granted accelerated approval for ELAHERE in folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) patients based on response data. Results from a confirmatory trial currently under review by the FDA show that ELAHERE is the first targeted agent to offer a survival benefit in PROC, with label expansion opportunities across larger segments of the ovarian cancer market.
ImmunoGen’s follow-on pipeline of ADCs further builds on AbbVie’s existing solid tumor pipeline of novel targeted therapies and next-generation immuno-oncology assets. Through focused R&D efforts, AbbVie has developed novel ADC technology and has unique strengths in antibody engineering, drug linker chemistry, and toxin research. AbbVie and ImmunoGen’s combined capabilities represent an opportunity to deliver potentially transformative ADC therapies to patients.
Overview of outsourcing trends 
